Radiant Innovation

Radiant Innovation FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of Radiant Innovation (3373.TWO) as of Nov 20, 2026 is 8.67 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was -24.46 % — a change of -135.46% (higher).

FCF Conversion

8.67 %

YoY

-135.46%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of Radiant Innovation is 2025 8.67 % . FCF Conversion Rate (FCF/EBITDA) of Radiant Innovation was 2024 -24.46 % . It decreases by -135.46% higher compared to the previous year.

The Radiant Innovation FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2018
26.55 TWD
Jan 1, 2019
220.35 TWD
Jan 1, 2020
101.53 TWD
Jan 1, 2021
-135.33 TWD
Jan 1, 2022
-154.14 TWD
Jan 1, 2023
10.00 TWD
Jan 1, 2024
-24.46 TWD
Jan 1, 2025
8.67 TWD
The Radiant Innovation FCF Conversion history
YEARFCF ConversionYoY
8.67 %-135.46%
-24.46 %-344.55%
10.00 %-106.49%
-154.14 %+13.90%
-135.33 %-233.29%
101.53 %-53.92%
220.35 %+729.97%
26.55 %-109.19%
-288.97 %-272.77%
167.26 %-290.57%
-87.77 %+14.50%
-76.65 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Radiant Innovation Stock analysis

What does Radiant Innovation do? Radiant Innovation Inc. generates revenue through the design, manufacture, and sale of infrared technology products. The company's main products include infrared temperature measurement instruments, ear temperature guns, frontal temperature guns, and other body temperature measurement products, alongside carbon dioxide detectors, infrared thermal imagers, and blood glucose dedicated chipsets. These products are distributed domestically and internationally across Asia, the Americas, Europe, and other regions. The primary buyers are healthcare providers, medical facilities, and electronic component distributors who require precise measurement tools and specialized components for health monitoring and diagnostics. The firm's product portfolio targets healthcare and industrial segments, with infrared thermal imagers used in building inspections and carbon dioxide detectors deployed in environmental monitoring. Blood glucose dedicated chipsets are supplied to medical device manufacturers for integration into diagnostic equipment. International distribution channels focus on regions like Asia, the Americas, and Europe, where demand for health-related measurement devices remains strong. Revenue streams are driven by direct sales to medical institutions, electronic component distributors, and industrial clients. The company's product lines serve both consumer-facing health monitoring applications and specialized industrial uses, with a strong emphasis on accuracy and reliability in temperature and gas detection technologies. Radiant Innovation is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Radiant Innovation stock

FCF Conversion Rate (FCF/EBITDA) of Radiant Innovation is 8.67 % in 2025.

FCF Conversion Rate (FCF/EBITDA) of Radiant Innovation changed from -24.46 % to 8.67 %, representing a -135.46% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) Radiant Innovation since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s Radiant Innovation with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Radiant Innovation

All Key Metrics — Radiant Innovation